Canada relies on foreign regulators for the majority of drug manufacturer inspections — but one of its biggest partners is falling behind
Drug manufacturers are tasked with formulating and producing the medications millions of Canadians take each day, from antibiotics to blood pressure medications.
We trust them to stick to strict standards — because quality issues can compromise treatments, worsen health outcomes, and in the most severe cases, make patients seriously ill.
New data obtained by CTV News from Health Canada shows that 85 per cent of inspections of drug manufacturing sites supplying the Canadian market were conducted by international regulators — not Health Canada.
Given the scale and complexity of the global pharmaceutical supply chain for both brand name and generic drugs, reliance on partners is necessary.
But the United States, which Canada relies on for 70 per cent of these inspections, has been facing an inspection backlog and remains behind its pre-pandemic inspection levels. Experts are raising concerns about how well the system can safeguard Canadians from substandard or dangerous medications.
US FDA logo
A U.S. Food and Drug Administration building is seen behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md., on Aug. 2, 2018. (AP Photo/Jacquelyn Martin, File)
David Ridley is a health economist at Duke University in North Carolina who has studied the U.S. Food and Drug Administration (FDA) drug manufacturer inspection system in the United States.
He said recent cuts to the regulator as part of the Department of Government Efficiency (DOGE) 'are disruptive and very stressful for FDA staff, but the problems with inspections date back for years, even decades.'
'Many of these establishments are not being inspected by Canadian or U.S. officials,' said Ridley. He warns of the risks of lax oversight, and 'we might get low quality products, products that don't work as well, aren't as stable, and in a very worst-case scenario…are toxic.'
U.S. inspections took a nosedive during the pandemic. Last year the Associated Press reported that nearly 2,000 drug plants were overdue for inspections.
The U.S. Government Accountability Office, an independent government agency that audits government activities at the request of congressional committees, has flagged the area of drug supply chain oversight as 'high risk' since 2009. The office said in a 2024 report that it 'has had long-standing concerns about FDA's ability to oversee the increasingly global drug supply chain.'
Matthew Herder, professor of law and medicine at Dalhousie University, specializes in the regulation of pharmaceuticals in Canada. He said knowledge that the biggest and most sophisticated regulator in the world is thin on the ground could potentially encourage lax practices. 'I worry that people will start to cut corners,' said Herder.
Past failures reveal the stakes
The drugs Canadians take are manufactured around the world. In 2024, 30.8 per cent of Canada's pharmaceutical imports originated from the United States, at least 33.5 per cent from European countries, 3.2 per cent from India, and 2.9 per cent from China — according to trade data from Statistics Canada.
Over the years the industry has been dogged with a series of safety lapses. In 2023, eye drops manufactured in India were recalled after contamination with drug resistant bacteria was discovered. The products were traced to three deaths and eight cases of blindness in the United States, according to the New York Times.
Eye drops
A selection of eye drops line a shelf at a pharmacy in Los Angeles on Dec. 12, 2023. Repeated recalls of eyedrops were drawing new attention to the limited powers U.S. regulators have to oversee medical products made overseas. Unlike prescription drugs, eyedrops and other over-the-counter products don't get preliminary review by the FDA. (AP Photo/Richard Vogel)
The FDA reported more than 100 people died after taking a common blood thinner that was recalled in 2007 due to contamination with an unnatural chemical during manufacturing in China. Reporter Katherine Eban's 2019 book Bottle of Lies chronicled profit-motivated fraud and deceit at Indian generic pharmaceutical company Ranbaxy in a decade-long investigation.
In recent years in Canada, drugs have been recalled for manufacturing issues like microbial and latex contamination. Mina Tadrous, the Canada research chair in real-world evidence and pharmaceutical policy and an associate professor at University of Toronto, estimates that the 2018 recall of valsartan for nitrosamine impurities (considered probable human carcinogens) led 200,000 patients to switch prescriptions in a single month in Canada. The recall rippled through the health care system causing disruptions for patients, doctors and pharmacists.
While toxic contamination is a worst-case scenario, the most common impact is more insidious, said Ridley. 'If the product is low quality, the most likely outcome is it's just not going to be as effective. And that's going to be really hard for people to notice.'
Ineffective prescription drugs can lead to failed treatments, prolonged illness, drug resistance, and a loss of trust in healthcare.
'Pharmacists count on a strong regulatory system to make sure medications are safe and high-quality,' said Tyler Gogo, senior manager of communications at the Canadian Pharmacists Association in an emailed statement. He said when that system falls short, 'it can cause real problems in delivering care.'
Reliance on foreign regulators
As of March 31, 2025, Canada's drug supply relied on 927 facilities within the country and 5,024 located abroad. Last fiscal year, Health Canada conducted 312 domestic onsite inspections, 47 foreign onsite inspections and relied on information from trusted international regulatory partners like the FDA, for another 2086 site inspections.
Like the United States, Canada halted international inspections in 2020 due to pandemic-related travel restrictions. While the inspections resumed, they did not increase to make up for the missed year. However, Health Canada said it does not have any backlogs for planned inspections.
'That's the strength of the reliance model,' said Kim Godard, Director General, Health Product Compliance Directorate at Health Canada, 'everyone kind of pitches in, we're not in the same situation in terms of creating huge backlogs.'
The number of facilities and the scope of the industry outstrips the resources of any single regulator. 'It makes sense to rely on partners,' said Ridley. 'The FDA is so big and the United States is so big. We have the scale. It does make sense to partner with us. But that's conditional on being able to count on us to make those foreign trips.' But Ridley said the U.S. has struggled to staff foreign offices in India and China, major sources of active ingredients in drugs.
Regarding the situation in the United States, Health Canada's Godard said 'there's no concern right now in Canada.' She said if a site is particularly important, gaps will be filled in by Canadian inspectors or another partner like Australia.
Industry pressures and generic drugs
Concerns about inspection protocols come at a time when parts of the industry are under increasing pressure to produce drugs more cheaply.
'I worry most about generic manufacturers because they are in this race to the bottom with their competitors,' said Ridley. He said major U.S. drug purchasers, retailers and wholesalers are looking for the cheapest generic.
Generic manufacturers in Canada face similar pressures. 'There's a potential disconnect between how we pay for drugs and our supply chain,' said Tadrous. He said though many hospitals look closely at where they source medications from, drug selection processes in Canada haven't always considered how or where a drug is made.
'For a very long period of time they have been agnostic to how drugs enter the country and the regulator and the payers have sort of been separate,' he said.
Generics make up about 20 per cent of product sales by value and 75 per cent of the market share by prescriptions in Canada, according to IQVIA Pharmafocus 2027, a global forecast on pharmaceutical trends used by Health Canada. Expanded national pharmacare is likely to increase demand for generics.
Last year Health Canada recalled three generic drugs (Accel-Ondansetron ODT, Mint-Betahistine and PMS-Pirfenidone) due to serious data integrity issues found at India-based Synapse Labs, the site that had tested the products. The European Medicines Agency identified 'irregularities in study data,' raising serious concerns about the bioequivalence of the drugs. Following the recall, the makers of Accel-Ondansetron ODT and Mint-Betahistine submitted new bioequivalence data, according to Health Canada. The regulator concluded the drugs to be safe and equivalent to the brand-name drugs and has granted approval for them to resume selling the products.
When asked if industry pressures in the generics space was a concern the department said, 'Health Canada has not identified significant ongoing compliance concerns specific to generic drug manufacturers.'
Despite concerns about oversight gaps and mounting pressure on regulators around the world, Health Canada said it is actively adapting. 'We're following the context, we're following the trends, we're following the technologies, we're following what's happening in the pharmaceutical industry to make sure that we're able to meet the demands of tomorrow,' said Godard.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
31 minutes ago
- Globe and Mail
Exact Sciences Schedules Second Quarter 2025 Earnings Call
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2025 webcast & conference call details A replay of the webcast will be available at The webcast, conference call, and replay are open to all interested parties. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company's growing portfolio includes well-established brands such as Cologuard ® and Oncotype DX ®, along with innovative solutions like Oncodetect™ for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit follow @ExactSciences on X, or connect on LinkedIn and Facebook.
CTV News
31 minutes ago
- CTV News
Obesity rates in Canada increased faster during pandemic than in previous 11 years
A closeup of a beam scale in New York, Tuesday, April 3, 2018. THE CANADIAN PRESS/AP-Patrick Sison TORONTO — A new report says the prevalence of obesity increased faster during the COVID-19 pandemic than it did over the course of more than a decade beforehand, specifically in young adults. The research published in the Canadian Medical Association Journal looked at obesity rates over a 15-year period based on the body mass index of almost 750,000 people who were 18 or older. Researchers say they saw an increase of about eight per cent over the first 11 years of the study, from 2009 to 2020, compared to an increase of more than one percentage point a year between 2020 and 2023. That's about twice the pre-pandemic rate of increase. Laura Anderson, the study's author and an associate professor at McMaster University, says these findings suggest public health restrictions during the COVID-19 pandemic may have had an impact on obesity rates. Anderson says there was a 'steep increase' in obesity rates among young adults, particularly young females, who showed an increase of 4.7 per cent between 2020 and 2023 in the youngest age group. Dr. Mélanie Henderson, a pediatric endocrinologist and researcher at the CHU Sainte-Justine, says the closure of gyms, extracurricular programs, schools and workplaces led to an absence of structure, extra screen time and closer proximity to the fridge. 'It was kind of the perfect storm,' says Henderson, who had no connection to the study. She adds that adolescence is a vulnerable time that could have made younger adults more susceptible to pandemic conditions. The study also suggests that stress related to changes in job status or caregiving may have led to weight gain for some. But it also says further study is needed to better understand the causes and how they can be prevented in the future. Henderson says the first step is creating policies that ensure health-care services are available to treat and manage obesity. This report by The Canadian Press was first published July 14, 2025. Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content. Hannah Alberga, The Canadian Press
CBC
an hour ago
- CBC
'Keep the doors open': As ERs close, doctor speaks out on the challenges of practising in rural Sask.
The senior lead physician of a Saskatchewan Medical Association program that provides help for rural doctors is speaking out on the challenges they face, after a number of temporary rural emergency room closures forced by a shortage of medical professionals in the province. "We tend to get the feeling that from an emergency perspective … the importance is placed on just keeping the door open, not necessarily, you know, keeping the door open when we are adequately staffed," Dr. Francois Reitz said in an interview Tuesday, as he was coming off a 24-hour emergency room shift. Reitz works with the medical association's rural relief program, which provides short-term locum relief to general and family doctors working in rural communities with fewer than five practising physicians. The workload for health-care workers in rural areas has increased from when he first started with the program 20 years ago, he said, including greater demand from patients as health conditions have become more complex. At the same time, there is a shortage of health-care workers in rural areas. "It's not just physician shortages that we're seeing," Reitz said. "My nursing colleagues, my pharmacy colleagues, my lab techs, etc. — there's a shortage of everybody." That's resulted in many rural health-care workers who are on call "every single day," he said, which means they struggle with work-life balance or may have to reduce services. When somebody calls in sick, there's often nobody to replace them, Reitz said. "I need certain things to be able to deal with the heart attack or if there's a motor vehicle accident," he said. "If I don't have those resources available to me, I cannot do the best that I can from a rural perspective. And rural, classically, we deal with fewer resources that we have to juggle." The expectation to "keep the doors open" for health services like emergency rooms can compromise the quality of care for patients, which is top of mind for doctors, said Reitz. "Our concerns are more about not being able to provide that quality of care," he said. "When one hasn't had sleep or [doesn't] have enough staff, what is slipping through the cracks?" Shortage has been approaching for years Reitz said the current doctor shortage is not a complete surprise. He said by 2018-19, it was known the field would run into a "mass retiring of doctors," due to the number of baby boomers working at that time. Then came the COVID-19 pandemic, which was both a wake-up call and catalyst for the health-care system, he said. "I think it highlighted a lot of weaknesses within our health-care system, both with current planning and future management," said Reitz. Many health-care workers also started to reassess their roles within the system and opted for better work-life balance, leading some to restrict their practices. Residents and leaders in some rural Saskatchewan communities have started to speak out about the shortage of doctors, and how many resign early. That comes down to a few factors, said Reitz. As the population grows, the province is not producing enough physicians to replace those who leave the field, he said. Instead, Reitz said Canada has relied heavily on international medical graduates — he was recruited from South Africa just over 20 years ago. "You are more likely to find an international medical graduate in rural Saskatchewan than you are to find a Canadian graduate," he said. Typically, a rural doctor will do a roughly five-year term, Reitz said. But as recruitment relies more heavily on international doctors, there seems to be fewer who stay in rural areas long-term. For those from some religious or cultural backgrounds, it can be hard to access community, traditional foods or religious services in rural areas, he said. "Saskatchewan has traditionally been very, very difficult for international medical graduates who are not of a Christian or atheist background," Reitz said. Many come to realize they would be "happier, healthier and in a better financial state after a year … moving anywhere else, whether it's centrally or out of province," he said. Pay is another factor in turnover, with the compensation not always matching the long hours rural physicians are expected to work, said Reitz. "Being a physician is not the high-paying job that it used to be 20 or 30 years ago," he said. "But then again, how do you sell to the public that a doctor is not being adequately paid? This is something which both culturally, as well as historically, is a very difficult argument to make." 'We have a lot of interest' The head of the Saskatchewan Healthcare Recruitment Agency says it works with international applicants to try to ease the transition. "Once we are aware of an applicant, we start working with them to understand where they were educated, what their currency or practice is, if they would be new to Canada," said chief executive officer Terri Strunk. The provincial agency's role is to reach out to medical residents and graduates locally, nationally and globally to try to find physicians, she said. There are many qualifications that have to be met through the Royal College of Physicians and Surgeons of Canada, the national regulatory body, she said. Once a doctor is deemed eligible, the College of Physicians and Surgeons of Saskatchewan and the Saskatchewan Health Authority work to determine which vacancy they could fill, said Strunk. The province offers competitive incentives and opportunities to doctors, and "we have a lot of interest in Saskatchewan because of the nature of our physician workforce here," she said. "They want to make that decision, and then what's the fastest way I can get there." With that, there needs to be consideration for international workers around where they should be located and how they can best be prepared to practise there, said Strunk. "Practising in a rural area of Saskatchewan is different from practising in one of our rural centres," she said. "You might have a physician, you know, practising in a remote or rural community of Saskatchewan that may have never seen … an agricultural accident before." The recruitment agency has worked hard over the last year to share information with communities about which factors influence retention of health-care workers in rural and remote areas, said Strunk. "Communities are the first to want to keep their health facilities open — they want to keep their doctors there, but oftentimes they don't know what they don't know," she said. "They may not realize that … [doctor] might be feeling socially isolated, or perhaps the spouse hasn't been able to find work." The agency is also looking at what has worked for communities that have good retention, and sharing that with others through a health-care tool kit. "It's just also about making sure that we, as a recruitment agency … and the employer at the Saskatchewan Health Authority and that community know who that physician is, what their needs are, as much as we can," Strunk said.
